Register today for our free, on-demand webinar and learn from our experts how you can drive double-digit pull-through gains in 2018: “Pull-through Breakthrough: How Your Peers Are Driving Double-Digit Gains Now and How You Can in ’18” (more…)
PHE Scientific Advisor Anupam Jena, coauthor of a new study on preeclampsia in the September issue of American Journal of Obstetrics & Gynecology, discussed the study’s findings and the growing economic impact of the condition with the Orlando Sentinel’s Amelia Cheatham. (more…)
In a new article appearing in the latest MM&M, Precision for Value EVP and Managing Partner Kelly Wilder shares her perspective on the challenges of marketing new heart drugs. (more…)
Maureen Hennessey, Senior Vice President, Director of Quality and Population Health Solutions for Precision for Value, will be giving a presentation on oncology quality at the 10th Annual Oncology Economics Forum, to be held on July 20th and 21st, 2017 at the Hilton Philadelphia (Penn’s Landing) in Philadelphia, PA.
Dr. Hennessey’s presentation will take place at 3:30pm on July 20th. (more…)
Precision for Value is pleased to announce it has again been named to MM&M magazine’s Top 100 Healthcare Agencies. In fact, this is the third straight year that Precision for Value has made the prestigious list, dating to the introduction of the PFV brand in 2015. (more…)
After spending millions on R&D just to get a product to market—and millions more promoting it—there’s nothing worse than when a launch falls flat. In a just-published panorama on PM360, Precision for Value’s Kelly Wilder identifies several critical mistakes that pharma companies make that can reduce the perceived value of a product in the marketplace. (more…)
In this month’s Drug Topics, correspondent Kathleen Gannon Longo talks with Precision for Value’s Jeremy Schafer on the potentially tremendous impact that value assessments will have on future patient reimbursement decisions. (more…)
During the recent ISPOR conference, Ross Maclean, Precision Health Economics’ SVP, Head of Medical, sat down to talk with Med Ad News’ Christiane Truelove on new opportunities for payer access in light of new FDA draft guidance around section 3037 of the 21st Century Cures Act. (more…)
In a new commentary appearing in The Wall Street Journal, Precision Health Economics cofounders Dana Goldman and Darius Lakdawalla turn to the national pastime to provide a fresh perspective on the issue of drug pricing and the return on investment pharmaceutical companies need to sustain innovation. (more…)
In a new commentary for PharmExec.com, Precision for Value SVP and Managing Director Jackie De Angelis outlines some of the most common mistakes that hinder access when launching a new drug. (more…)